Concepedia

Graham Temple

GT

Statistics

Publications

12

Citations

844

H-Index

12

Active since

2005

Affiliations

Boehringer Ingelheim (United Kingdom)(Current)

Royal Marsden Hospital

Boehringer Ingelheim (Germany)

Addenbrooke's Hospital

Cancer Research UK

Graham Temple is an author at Boehringer Ingelheim (United Kingdom) specializing in cancer pharmacology, oncology, and medicine.

Publications per year

2005–2015

12

Publications

12

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

Timothy A. Yap, Laura Vidal, Jan Adam et al. · Journal of Clinical Oncology · 2010 · 344 citations · Full text

, , +16

Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer

Jonathan A. Ledermann, Allan Hackshaw, Stan Kaye et al. · Journal of Clinical Oncology · 2011 · 214 citations

, , +16

Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study

Tim Eisen, Yaroslav Shparyk, Nicholas MacLeod et al. · Investigational New Drugs · 2013 · 52 citations

, , +9

A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC)

Jonathan A. Ledermann, Gordon Rustin, A. Hackshaw et al. · Journal of Clinical Oncology · 2009 · 44 citations

, , +15

A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results

Tim Eisen, A-B. Loembé, Yaroslav Shparyk et al. · British Journal of Cancer · 2015 · 36 citations · Full text

, , +14

1–5 of 12